Gravitate Health FHIR Implementation Guide, published by Gravitate Health Project. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/joofio/test-epi-composition/ and changes regularly. See the Directory of published versions
Full name:
Authorised dose form:
Legal status of supply:
Domain:
Resource status:
Product classification:
Document Details
Generated Narrative: Bundle TEST PURPOSES ONLY - doptelet
Language: en
Profile: Bundle - ePI
Final Document at 2022-02-16 13:28:17+0000 by Organization ACME industry for Bundle: identifier = http://ema.europa.eu/identifier#None; type = document; timestamp = 2023-06-27 10:09:22+0000
Document Subject
Generated Narrative: MedicinalProductDefinition mpfe68e84ae2a5a5a43e0a98992e2c4775
identifier: http://ema.europa.eu/identifier
/EU/1/19/1373/001
type: Medicinal Product
domain: Human use
status: active
legalStatusOfSupply: Medicinal product subject to medical prescription
name
productName: Doptelet 20 mg film-coated tablets
type: Full name
part
part: nan
type: Invented name part
part
part: nan
type: Scientific name part
part
part: nan
type: Strength part
part
part: nan
type: Pharmaceutical dose form part
Usages
Country Jurisdiction Language EU EU en
Document Content
Generated Narrative: Composition composition-en-fe68e84ae2a5a5a43e0a98992e2c4775
Language: en
Profile: Composition (ePI)
identifier: http://ema.europa.eu/identifier
/EU/1/19/1373/001
status: Final
type: Package Leaflet
category: Raw
date: 2022-02-16 13:28:17+0000
author: Organization ACME industry
title: TEST PURPOSES ONLY - doptelet
Mode | Time |
Official | 2022-02-16 13:28:17+0000 |
What is in this leaflet
Doptelet contains an active substance called avatrombopag. It belongs to a group of medicines called thrombopoietin receptor agonists.
Doptelet is used in adults with chronic liver disease to treat low platelet count (called thrombocytopenia) before having a medical procedure where there is a risk of bleeding.
Doptelet is used to treat adults with low platelet counts due to primary chronic immune thrombocytopenia (ITP) when a prior treatment for ITP (such as corticosteroids or immunoglobulins) has not worked well enough. Doptelet works by helping to increase the number of platelets in the blood. Platelets are blood cells that help the blood to clot and so reduce or prevent bleeding.
Do not take Doptelet
Warnings and precautions Talk to your doctor or pharmacist before taking Doptelet if:
You may be at higher risk of blood clots as you get older or if:
If any of the above applies to you, or you are not sure, talk to your doctor or pharmacist before taking Doptelet.
Blood tests for platelet count If you stop taking Doptelet, your platelet count is likely to become low as before treatment or even lower, with a risk of bleeding. This may happen within days. The platelet count will be monitored, and your doctor will discuss appropriate precautions with you.
Tests to check your bone marrow In people who have problems with their bone marrow, medicines like Doptelet could make the problems worse. Signs of bone marrow changes may show up as abnormal results in your blood tests. Your doctor may also carry out a test to directly check your bone marrow during treatment with Doptelet.
Children and adolescents Do not give Doptelet to people less than 18 years old. The safety and effectiveness of this medicine in this age group is not known.
Other medicines and Doptelet
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.
If you are taking other medicines for ITP, you may need to take a lower dose or to stop taking them while you are taking Doptelet.
Pregnancy and breast-feeding
If you are pregnant, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine. Doptelet is not recommended in pregnancy and in women who are able to have children and are not using contraception.
If you are breast-feeding, ask your doctor or pharmacist for advice before taking Doptelet. This medicine can pass into breast milk. Your doctor will help you decide whether the benefit of breast-feeding outweighs any possible risks to your baby while you are breast-feeding.
Driving and using machines Doptelet is not expected to affect you being able to drive, cycle or use tools or machines.
Doptelet contains lactose Doptelet contains lactose (a type of sugar). If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine.
Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.
If you have chronic liver disease and low platelet count you should be scheduled to undergo your procedure 5 to 8 days after the last dose of Doptelet.
If you have chronic ITP your doctor will tell you how much Doptelet to take and how often to take it.
How much to take
If you have chronic liver disease and are scheduled for an invasive procedure
If you have chronic ITP
Taking this medicine
If you have chronic liver disease and low platelet count
If you have chronic ITP
If you take more Doptelet than you should
If you forget to take Doptelet
If you stop taking Doptelet Take Doptelet for as long as your doctor tells you. Do not stop taking Doptelet unless your doctor tells you to.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Tell your doctor or pharmacist if you notice any of the following side effects.
The following side effects have been reported to be associated with treatment with Doptelet in adult patients with chronic liver disease:
Common (may affect up to 1 in 10 people)
Uncommon (may affect up to 1 in 100 people)
Not known (frequency cannot be estimated from the available data)
The following side effects have been reported to be associated with treatment with Doptelet in adult patients with primary chronic ITP:
Very common (may affect more than 1 in 10 people)
Common (may affect up to 1 in 10 people)
Common side effects that may show up in blood tests
Uncommon (may affect up to 1 in 100 people)
Uncommon side effects that may show up in blood tests
Not known (frequency cannot be estimated from the available data)
Reporting of side effects If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the carton and on each blister after EXP . The expiry date refers to the last day of that month.
This medicine does not require any special storage conditions.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help to protect the environment.
What Doptelet contains
The active substance is avatrombopag. Each film-coated tablet contains avatrombopag maleate equivalent to 20 mg of avatrombopag.
The other ingredients are: Tablet core: lactose monohydrate (see section 2 Doptelet contains lactose ); microcrystalline cellulose [E460(i)]; crospovidone type B [E1202]; silica, colloidal anhydrous [E551]; magnesium stearate [E470b]. Film coating: poly(vinyl alcohol) [E1203]; talc [E553b]; macrogol 3350 [E1521]; titanium dioxide [E171]; iron oxide yellow [E172].
What Doptelet looks like and contents of the pack Doptelet 20 mg film-coated tablets (tablets) are pale yellow, round, rounded on the upper and lower side, marked with AVA imprinted on one side and 20 on the other.
The tablets are supplied in cartons containing one or two aluminium blisters. Each blister contains either 10 or 15 tablets.
Marketing Authorisation Holder Swedish Orphan Biovitrum AB (publ) SE-112 76 Stockholm
Sweden
Manufacturer Swedish Orphan Biovitrum AB (publ) Strandbergsgatan 49, Stockholm, SE-112 Sweden
This leaflet was last revised in .
Detailed information on this medicine is available on the European Medicines Agency web site:
Entry 1 - fullUrl = Composition/composition-en-fe68e84ae2a5a5a43e0a98992e2c4775
Resource Composition:
Generated Narrative: Composition composition-en-fe68e84ae2a5a5a43e0a98992e2c4775
Language: en
Profile: Composition (ePI)
identifier:
http://ema.europa.eu/identifier
/EU/1/19/1373/001status: Final
type: Package Leaflet
category: Raw
date: 2022-02-16 13:28:17+0000
author: Organization ACME industry
title: TEST PURPOSES ONLY - doptelet
Attesters
Mode Time Official 2022-02-16 13:28:17+0000
Entry 2 - fullUrl = MedicinalProductDefinition/mpfe68e84ae2a5a5a43e0a98992e2c4775
Resource MedicinalProductDefinition:
Generated Narrative: MedicinalProductDefinition mpfe68e84ae2a5a5a43e0a98992e2c4775
identifier:
http://ema.europa.eu/identifier
/EU/1/19/1373/001type: Medicinal Product
domain: Human use
status: active
legalStatusOfSupply: Medicinal product subject to medical prescription
name
productName: Doptelet 20 mg film-coated tablets
type: Full name
part
part: nan
type: Invented name part
part
part: nan
type: Scientific name part
part
part: nan
type: Strength part
part
part: nan
type: Pharmaceutical dose form part
Usages
Country Jurisdiction Language EU EU en